Login / Signup

PSMA-positive circulating tumor cell detection and outcomes with abiraterone or enzalutamide treatment in men with metastatic castrate resistant prostate cancer.

Santosh GuptaSusan HalabiQian YangAkash RoyAlisa TubbsYamini GoreDaniel J GeorgeDavid M NanusEmmanuel S AntonarakisDaniel Costin DanilaRussell Zelig SzmulewitzRichard WenstrupAndrew J Armstrong
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
We observed PSMA CTC heterogeneity between and within patients with mCRPC over time during abi/enza progression. CTC PSMA enumeration was adversely prognostic independent of clinical factors and disease burden. Further validation is warranted in the context of PSMA-targeted therapies.
Keyphrases